100% of every donation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed more than $120 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2014  |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2011 Research Grants

Kenneth Scott, Ph.D.
In Vivo Positive Selection Screening for Somatic MutationDrivers of Pancreatic Cancer Metastasis
Baylor College of Medicine

Kenneth Olive, Ph.D.
Preclinical Evaluation of the Mutant-Ras Synthetic Lethal Drug MEII
Columbia University

Ralph Hruban, M.D. 
Sequencing the Familial Pancreatic Cancer Genomes Part 2
Johns Hopkins University

Daniel Laheru, M.D. 
Ana De Jesus-Acosta, M.D.
Phase II study of Gemcitabine and Abraxane in Combination with Vismodegib (GDC-0449), a Hedgehog Pathway Inhibitor, in Patients with Previously Untreated Mestastatic Adenocarcinnoma of the Pancreas. 
Johns Hopkins University

Anne Le, Ph.D.
Targeting Pancreatic Cancer Metabolism
Johns Hopkins University

Lei Zheng,M.D., Ph.D.
Annexin A2, a Newly Identified Pro-Metastasis Tumor Antigen as a Target for Pancreatic Cancer Therapy
Johns Hopkins University

Jeff Engleman, M.D., Ph.D.
Identification of Novel KRAS-directed Targeted Therapy Combination Strategies for Pancreatic Cancer.
Massachusetts General Hospital

Rakesh Jain, Ph.D.
Robert Langer, Ph.D.
Seeking to Improve Drug Delivery in Pancreatic Cancer by Widenine Blood Vessels Surrounding the Cancer to More Effective Access the Tumor.
Massachusetts General Hospital
Massachusetts Institute of Technology

Hidde Ploegh, Ph.D. 
Kai Wucherpfenning,M.D., Ph.D.
Christopher Love, Ph.D.
Seeks to Develop a Mouse Model that Would Mimic the Human Immune System, Which Could then be used as a Tool to help Develop Immunotherapy Agents for Human Trails.
Massachusetts Institute of Technology
Dana-Farber Cancer Institute

Matthew Vander Heiden, M.D., Ph.D.
Metabolism and Pancreatic Cancer Pathogenesis: A Multi-Institutional Approach to Define Novel Screening Modalities and Treatments for Pancreatic Cancer.
Massachusetts Institute of Technology

Eileen O'Reilly, M.D.
A Phase II Study to try a Drug Combination in BRCA Mutated Pancreatic Cancers that was Successful in BRCA Mutated Breast Cancers.
Memorial SloanKettering Cancer Center

Eileen Friedman, Ph.D.
A ROS- Controlling Kinase in Pancreatic Cancer.
SUNY Upstate Medical University

Michael Karin, Ph.D.
Pathogehic Functions of IKKa, p62 and Impaired Autophagy in Pancreatic Cancer
The Regents of the University of California

Judith Varner, Ph.D.
Selective Inhibitors of Inflammation as a New Therapeutic Approach for Pancreatic Cancer
University of California, San Diego

Wells Messersmith, M.D.
Anirban Maitre, M.B.B.S.
A Phase II Study to Assess a New Drug for Pancreatic Cancer made by Roche
Univesity of Colorado
Johns Hopkins University

Channing Der, Ph.D.
Study Drug Combinations Surrounding the ERK and K-ras Pathways in a Novel Cell Culture System (3DSpheroids) to Identify Promising Drug Combinations that can be used in Clinical Trials.
University of North Carolina

Gauri Varadachary, M.B.B.S., M.D.
A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies
University of Texas, M.D. Anderson Cancer Center

David DeNardo, Ph.D.
Targeting Tumor-Associated Macrophages to Overcome Chemotherapeutic Resistance in Pancreatic Cancer
Washington University

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303